First-in-Class Precision Against Nectin-4: Padcev
In this edition of ADC Spotlight, Sneha explores Padcev, the first Nectin-4 directed ADC that addressed a long-standing unmet need in advanced urothelial carcinoma. By providing a new and effective treatment option for patients, Padcev underscores the growing potential of ADCs in transforming cancer therapy. This snapshot captures its story from development to impact, tracing […]
From Biparatopic to Tetravalent: Overcoming the Next Frontier in ADC Antibody Engineering
How far can antibody engineering take ADCs—and what challenges stand in the way? In this new MedNess feature, Suhail Ahmed Kabeer Rasheed examines the leap from biparatopic to tetravalent antibody-drug conjugates, unpacking how higher valency is tackling tumor heterogeneity and internalization resistance. Discover why tetravalency has become the next frontier after biparatopic platforms: what it means for […]
Fat or Carbs? How Brain Process our Food Choices
In this article, Neeba Wilson explores the fascinating neuroscience behind why our cravings vary between fries and frosted treats. According to recent studies published in Metabolism (October 2025), discover how certain brain networks within the hypothalamus govern our preference for fats over carbs. Learn how CRH neurons trigger carb cravings during energy stress, how MC4R […]
Pushing the Boundaries of HER2 Therapy: Enhertu
In this edition of ADC Spotlight, Sneha traces the rise of Enhertu, the next-generation HER2-directed ADC that redefined the therapeutic landscape of breast and other solid tumors. Building on Kadcyla’s foundation, Enhertu demonstrated the power of innovative linker and a higher DAR, setting new benchmarks for efficacy and expanding the boundaries of HER2-directed treatment. (Click […]
1. Experimental Design: (A) The Readouts
In this article, Aditi Sharma addresses the critical preliminary phase of flow cytometry experimental design. It posits that the crucial initial step is to Define the Readout Strategy. This methodical approach ensures the experimental design possesses a sound biological rationale, setting the foundation for the subsequent technical steps of fluorochrome selection. (Click anywhere on the […]
Introduction to the Series
Welcome to the weekly Flow Cytometry Technical Series, a comprehensive resource designed to demystify the complexities of flow cytometry and empower researchers, students, and technical specialists with the knowledge to excel in their experiments. This series delves into the core issues and advanced applications of flow cytometry, offering detailed technical analysis and practical solutions. What […]
A Pioneer’s Journey from Setback to Resurgence: Mylotarg
In this edition of ADC Spotlight, Sneha revisits Mylotarg, the first FDA approved ADC targeting CD33 in AML. Mylotarg’s journey reflects both the promise and challenges of early ADC design. This snapshot captures how, despite its early setbacks, Mylotarg’s revival paved the way for safer and more effective generations of ADCs that followed. Disclaimer The […]
Visby Medical Women’s Sexual Health Test
In this edition, Krishnangi explores the Visby Medical Women’s Sexual Health Test, the first FDA authorized at home PCR assay for sexually transmitted infections. Through her coverage, Krishnangi highlights the assay’s technological foundation, clinical validation, and its potential to expand women’s access to timely and accurate STI diagnosis. Disclaimer The editors take care to share authentic information. In […]
Schizophrenia: Clinical Trials
“Continuing the quest to understand schizophrenia, this article explores the latest clinical trials that aim to improve care and uncover new insights into this complex disorder.” Disclaimer The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org The sponsors do not have any influence on the nature or kind […]
Biparatopic Design: Engineering the Next Gen Antibodies for ADC Specific Functions
“Can antibodies be purposefully engineered for ADC success, or does ‘any antibody will do’? This week on MedNess, our ADC Spotlight series challenges the early assumption that repurposed therapeutic antibodies automatically make effective ADC scaffolds – revealing why internalization efficiency, not just target binding, determines clinical outcomes. In this feature, Suhail Ahmed Kabeer Rasheed, PhD, […]
Schizophrenia
Schizophrenia, a split mind? Not quite true. It’s the mind playing tricks on reality! Often mistaken for a personality disorder, schizophrenia is a condition in which the brain distorts perception, thought, and emotion. Learn about its underlying causes, symptoms, and treatments and the ongoing challenges in understanding this complex disorder. (Click anywhere on the image to expand) Disclaimer […]
Advancing Precision in Leukemia: Besponsa
In this edition of ADC Spotlight, Sneha delves into the story of Besponsa, the CD22-directed ADC that brought targeted precision to B-cell acute lymphoblastic leukemia (B-ALL). From its scientific rationale and mechanism of action to its clinical development, this snapshot traces how Besponsa advanced the role of ADCs in hematologic malignancies. Disclaimer The editors take […]
ADCs – The Precision Missiles with a Promising Future in Cancer Treatment
“How did we get from chemotherapy’s devastating side effects to today’s precision cancer treatments? This week on MedNess, our ADC Spotlight series traces the evolution of Antibody-Drug Conjugates (ADCs) – from early chemotherapy through targeted therapies to modern precision medicines that combine the targeting power of antibodies with the cell-killing potency of chemotherapy. In this detailed […]
Setting the stage for HER2 ADC Evolution: Kadcyla
In this edition of ADC Spotlight, Sneha traces the Journey of Kadcyla, from concept to clinic. As the first HER2-directed ADC, it initiated a new era in breast cancer therapy and paved the way for next-generation HER2 ADCs. This snapshot captures how Kadcyla set the stage for reshaping the treatment landscape of HER2+ve breast cancer. […]
Precision Power against CD30: Adcetris
In this edition of ADC Spotlight, Sneha delves into the journey of Adcetris – a pioneering ADC that reshaped treatment paradigms in heme malignancies. From its mechanism of action and scientific conception to regulatory milestones, this comprehensive snapshot offers valuable insights into the evolution and future potential of this targeted therapy. (Click anywhere on the image […]
Dual-Payload ADCs: Revolution in Precision Oncology?
In his debut article for the ADC Spotlight column, Suhail brings deep firsthand insight into ADC development to explore a major milestone in oncology: the approval of KH815, the first dual-payload ADC. He unpacks how orthogonal payload strategies could redefine the future of precision cancer therapy—and what needs to come next. (Click anywhere on the […]
Obsessive Compulsive Disorder (OCD): Treatment
In this issue of Inside The Mind, Ritu continues her focus on treatments available for OCD – the standard of care, attempts to find newer, better, safer alternatives, pipeline activity, options for glutamate-resistant patients, and what drives the management of these patients. Read more on troriluzole’s journey in the treatment of OCD. (Click anywhere on […]
First FDA‑cleared blood test for Alzheimer’s amyloid pathology: Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio
In this issue of Diagnostic Digest, Krishnangi explores the groundbreaking Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio Assay—the first FDA-approved blood test to aid in the diagnosis of Alzheimer’s disease. She highlights how this innovative test replaces invasive spinal taps and costly PET scans with a simple blood draw, offering a faster, less intrusive, and more accessible diagnostic […]
Obsessive Compulsive Disorder (OCD): Overview
In this issue of Inside The Mind, Ritu provides an insightful read on Obsessive-Compulsive Disorder (OCD): exploring what it is, its symptoms, risks, treatment options, management strategies, care pathways, and the challenges faced in developing new therapeutic options for it. A must-read for anyone looking to understand the condition and support those affected. (Click anywhere […]
Semaglutide, a GLP-1R agonist, is also effective for MASH patients
Semaglutide, manufactured by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus, is FDA-approved for type 2 diabetes and obesity patients. Additionally, it has been tested for other diseases, such as heart and renal diseases. In a recent publication in the NEJM journal, Novo Nordisk released its interim data on the phase 3 trial […]
Z for Zellweger Spectrum Disorders
Zellweger spectrum disorders (ZSD) are a group of rare, inherited conditions caused by mutations in genes responsible for building peroxisomes—tiny structures inside our cells that are crucial for breaking down fatty acids and supporting brain development. Though once considered distinct diseases, conditions like Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD) are now […]
Orforglipron -An oral GLP-1R agonist to treat type 2 diabetes
In a recent press release, Eli Lilly announced the key findings of its phase 3 trial of orforglipron, an oral GLP-1 receptor agonist in type 2 diabetes patients. The other GLP-1 analogues in the market to treat type 2 diabetes and obesity are administered by subcutaneous injection once a week. Comparatively, orforglipron is taken orally […]
Y For Yellow Fever
Yellow fever is a serious, mosquito-borne viral disease caused by a flavivirus, primarily affecting regions in tropical and subtropical Africa and South America. Although it is rare in countries like the United States, where the disease is not endemic, yellow fever remains a significant public health concern in parts of the world where the virus […]
Gut microbiota and its metabolites can predict anti-tumor immunotherapy efficacy
In a recent article published in the Cell Metabolism journal, scientists found that a combination of 12 gut microbes and 3 metabolites can predict the efficacy of anti-PD-1/PD-L1 therapy in various cancers with 88% sensitivity. Need for the study: Immunotherapy against cancer has revolutionized cancer treatment and has now become the standard of care. There […]
X for X-Linked Protoporphyria
X-linked protoporphyria (XLP) is a rare genetic disorder caused by mutations in the ALAS2 gene on the X chromosome. This gene encodes a protein called erythroid-specific 5-aminolevulinate synthase 2. Mutations in the ALAS2 lead to an overproduction of this enzyme, resulting in elevated levels of protoporphyrin IX. The excess protoporphyrin accumulates in the blood, liver, […]
W for Wilson Disease
Wilson disease is a rare, hereditary genetic ailment that impairs the body’s capacity to metabolize copper, resulting in its toxic buildup in essential organs such as the liver, brain, and eyes. Wilson disease results from mutations in the ATP7B gene, which facilitates the transport of excess copper from the liver to the bile for excretion […]
V for Von Hippel-Lindau Disease
Von Hippel-Lindau (VHL) disease is a rare, autosomal dominant genetic disorder caused by mutations in the VHL gene, a critical tumor suppressor gene. The VHL gene regulates the hypoxia-inducible factor (HIF) complex, which controls the production of growth factors like vascular endothelial growth factor (VEGF). Mutations in VHL disrupt this regulation, leading to increased growth […]
How Diet Coke causes atherosclerotic plaque – mechanism unlocked!!
It is known that high consumption of artificial sweeteners like aspartame can increase the risk of cardiovascular events but how it actually contributes to the disease is not clear. In the present study published in Cell Metabolism, the authors demonstrated its molecular mechanism in mice. They showed that an aspartame-rich diet in mice increased blood […]
U for Uveal Melanoma
Uveal melanoma, also known as ocular melanoma, is rare cancer that affects the uvea, the central layer of the eye. The uvea consists of the iris (the colored part of the eye), the ciliary body (which produces fluid for the eye), and the choroid (a layer of blood vessels under the retina). This disorder most […]
SYMBRAVO, A Fast-Acting, Dual-Action Drug to Relieve Migraine
Axsome Therapeutics’ SYMBRAVO was recently approved by the U.S. Food and Drug Administration (FDA). It combines a fast-acting serotonin receptor agonist, rizatriptan with meloxicam, a potent COX-2 preferential, nonsteroidal anti-inflammatory drug (NSAID). Using Molecular Solubility Enhanced Inclusion Complex (MoSEIC) rapid-absorption technology to speed up meloxicam absorption four times faster, SYMBRAVO offers quick relief for acute […]